The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
David A Jans, Kylie M Wagstaff
Biochemical and Biophysical Research Communications, doi:10.1016/j.bbrc.2020.10.042
a b s t r a c t FDA approved for parasitic indications, the small molecule ivermectin has been the focus of growing attention in the last 8 years due to its potential as an antiviral. We first identified ivermectin in a high throughput compound library screen as an agent potently able to inhibit recognition of the nuclear localizing Human Immunodeficiency Virus-1 (HIV-1) integrase protein by the host importin (IMP) a/b1 heterodimer, and recently demonstrated its ability to bind directly to IMPa to cause conformational changes that prevent its function in nuclear import of key viral as well as host proteins. Cell culture experiments have shown robust antiviral action towards a whole range of viruses, including HIV-1, dengue, Zika and West Nile Virus, Venezuelan equine encephalitis virus, Chikungunya, pseudorabies virus, adenovirus, and SARS-CoV-2 (COVID-19). Close to 70 clinical trials are currently in progress worldwide for SARS-CoV-2. Although few of these studies have been completed, the results that are available, as well as those from observational/retrospective studies, indicate clinical benefit. Here we discuss the case for ivermectin as a host-directed broad-spectrum antiviral agent, including for SARS-CoV-2.
Author contributions Conceptualization, D.A.J.; writingdoriginal draft preparation, D.A.J., K.M.W.; review and editing, D.A.J., K.M.W. Both authors have read and agreed to the published version of the manuscript.
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Alam, Murshed, Bhiuyan, Saber, Alam et al., A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline, Bangladesh Coll. Phys. Surg,
doi:10.3329/jbcps.v38i0.47512Arshad, Pertinez, Box, Tatham, Rajoli et al., Prioritisation of anti-SARS-cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics, Clin. Pharmacol. Ther,
doi:10.1002/cpt.1909Atkinson, Audsley, Lieu, Marsh, Thomas et al., Recognition by host nuclear transport proteins drives disorder-to-order transition in Hendra virus V, Sci. Rep
Bennett, Zhao, Bosard, Imperiale, Role of a nuclear localization signal on the minor capsid proteins VP2 and VP3 in BKPyV nuclear entry, Virology
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir. Res
Caly, Wagstaff, Jans, Nuclear trafficking of proteins from RNA viruses: potential target for anti-virals?, Antivir. Res
Changeux, Amoura, Rey, Miyara, A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications, Comptes Rendus Biol
Ci, Li, Yu, Zhang, Yu et al., Avermectin exerts antiinflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway, Fund. Clin. Pharmacol,
doi:10.1111/j.1472-8206.2009.00684.xCrump, Omura, Ivermectin, wonder drug from Japan: the human use perspective, Proc. Jpn. Acad
Crump, Omura, Ivermectin: panacea for resource-poor communities ?, Trends Parasitol
Espitia-Hernandez, Munguia, Diaz-Chiguer, Lopez-Elizalde, Jimenez-Ponce, Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: a proof of concept study, Biomed. Res
Fraser, Watanabe, Wang, Chan, Maher et al., A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection, J. Infect. Dis,
doi:10.1093/infdis/jiu319Frieman, Yount, Heise, Kopecky-Bromberg, Palese et al., Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/golgi membrane, J. Virol
Fulcher, Jans, Regulation of nucleocytoplasmic trafficking of viral proteins; an integral role in pathogenesis ?, Biochim. Biophys. Acta Mol. Cell Res
Gonz Alez Canga, Sahagún Prieto, Diez Li Ebana, Fern Andez Martínez, Sierra et al., The pharmacokinetics and interactions of ivermectin in humans -a mini-review, AAPS J
Gotz, Magar, Dornfeld, Giese, Pohlmann et al., Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci. Rep
Guzzo, Furtek, Porras, Chen, Tipping et al., Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J. Clin. Pharmacol
Jans, Martin, Wagstaff, Inhibitors of nuclear transport, Curr. Opin. Cell Biol
Khan, Khan, Debnath, Nath, Mahtab et al., Ivermectin Treatment May Improve the Prognosis of Patients with COVID-19, Archivos de Bronconeumologia,
doi:10.1016/j.arbres2020.08.007King, Tessier, Dodge, Weinberg, Mymryk, Inhibition of human adenovirus replication by the importin a/b1 nuclear import inhibitor ivermectin, J. Virol,
doi:10.1128/JVI.00710-20Krause, Buisson, Bertrand, Corringer, Galzi et al., A positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor, Mol. Pharmacol
Kumar, Jeyaraman, Jain, Anudeep, A wonder drug in the arsenal against COVID -19: medication evidence from ivermectin, J. Adv. Med. Med. Res
Lopez-Denman, Russo, Wagstaff, White, Jans et al., Nucleocytoplasmic shuttling of the West Nile virus RNAdependent RNA polymerase NS5 is critical to infection, Cell Microbiol,
doi:10.1111/cmi.12848Loukas, Hotez, Chemotherapy of helminth infections
Lundberg, Pinkhan, Baer, Amaya, Narayan et al., Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication, Antivir. Res
Lv, Liu, Wang, Dang, Qiu et al., Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antivir. Res
Mastrangelo, Pezzullo, De Burghgraeve, Kaptein, Pastorino et al., Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J. Antimicrob. Chemother
Navarro, Camprubí, Requena-M Endez, Buonfrate, Giorli et al., Safety of high-dose ivermectin: a systematic review and meta-analysis, J. Antimicrob. Chemother
Podder, Chowdhury, Sina, Haque, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study, IMC J. Med. Sci
Pryor, Rawlinson, Butcher, Barton, Waterhouse et al., Nuclear localization of dengue virus nonstructural protein 5 through its importin alpha/beta-recognized nuclear localization sequences is integral to viral infection, Traffic,
doi:10.1111/j.1600-0854.2007.00579.xRahman, Iqbal, Islam, Niaz, Hussain et al., Comparison of viral clearance between ivermectin with doxycycline and hydroxychloroquine with azithromycin in COVID-19 patients, Bangladesh Coll. Phys. Surg,
doi:10.3329/jbcps.v38i0.47514Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19 (ICON study), Chest,
doi:10.1016/j.chest.2020.10.009Schmith, Zhou, Lohmer, The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin. Pharmacol. Ther,
doi:10.1002/cpt.1889Tay, Fraser, Chan, Moreland, Rathore et al., Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antivir. Res
Thomas, Lundberg, Pinkhan, Shechter, Debono et al., Identification of novel antivirals inhibiting recognition of Venezuelan equine encephalitis virus capsid protein by the Importin a/b1 heterodimer through high-throughput screening, Antivir. Res
Twum-Danso, Meredith, Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis, Trop. Med. Int. Health
Varghese, Kaukinen, Glaesker, Bespalov, Hanski et al., Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses, Antivir. Res
Wagstaff, Headey, Telwatte, Tyssen, Hearps et al., Molecular dissection of an inhibitor targeting the HIV integrase dependent preintegration complex nuclear import, Cell Microbiol,
doi:10.1111/cmi.12953Wagstaff, Rawlinson, Hearps, Jans, An AlphaScreen(R)based assay for high-throughput screening for specific inhibitors of nuclear import, J. Biomol. Screen,
doi:10.1177/1087057110390360Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin a/b-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem. J
Yamasmith, Saleh-Arong, Avirutnan, Angkasekwinai, Mairiang et al., Efficacy and safety of ivermectin against dengue infection: a phase III, randomized, double-blind, placebo-controlled trial
Yang, Atkinson, Fraser, Wang, Maher et al., Novel flavivirus antiviral that targets the host nuclear transport importin a/b1 heterodimer, Cells,
doi:10.3390/cells8030281Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin a/b1 heterodimer, Antivir. Res
Yang, Ye, Zhu, Wang, Deng et al., Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets, Sci. Rep,
doi:10.1038/srep17554Zhang, Song, Ci, An, Ju et al., Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm. Res,
doi:10.1007/s00011-008-8007-8{ 'indexed': {'date-parts': [[2024, 2, 9]], 'date-time': '2024-02-09T20:43:09Z', 'timestamp': 1707511389652},
'reference-count': 49,
'publisher': 'Elsevier BV',
'license': [ { 'start': { 'date-parts': [[2021, 1, 1]],
'date-time': '2021-01-01T00:00:00Z',
'timestamp': 1609459200000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}],
'funder': [ { 'DOI': '10.13039/501100000925',
'name': 'National Health and Medical Research Council',
'doi-asserted-by': 'publisher',
'award': ['APP1002486/APP1103050', 'ECF-17-007']},
{ 'DOI': '10.13039/501100001026',
'name': 'National Breast Cancer Foundation',
'doi-asserted-by': 'publisher',
'award': ['APP1002486/APP1103050', 'ECF-17-007']}],
'content-domain': {'domain': ['elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True},
'published-print': {'date-parts': [[2021, 1]]},
'DOI': '10.1016/j.bbrc.2020.10.042',
'type': 'journal-article',
'created': { 'date-parts': [[2020, 10, 21]],
'date-time': '2020-10-21T21:17:37Z',
'timestamp': 1603315057000},
'page': '163-172',
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 30,
'title': 'The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?',
'prefix': '10.1016',
'volume': '538',
'author': [ { 'ORCID': 'http://orcid.org/0000-0001-5115-4745',
'authenticated-orcid': False,
'given': 'David A.',
'family': 'Jans',
'sequence': 'first',
'affiliation': []},
{'given': 'Kylie M.', 'family': 'Wagstaff', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'reference': [ { 'key': '10.1016/j.bbrc.2020.10.042_bib1',
'doi-asserted-by': 'crossref',
'first-page': '13',
'DOI': '10.2183/pjab.87.13',
'article-title': 'Ivermectin, wonder drug from Japan: the human use perspective',
'volume': '87',
'author': 'Crump',
'year': '2011',
'journal-title': 'Proc. Jpn. Acad.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib3',
'doi-asserted-by': 'crossref',
'first-page': '42',
'DOI': '10.1208/s12248-007-9000-9',
'article-title': 'The pharmacokinetics and interactions of ivermectin in humans - a '
'mini-review',
'volume': '10',
'author': 'González Canga',
'year': '2008',
'journal-title': 'AAPS J.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib4',
'doi-asserted-by': 'crossref',
'first-page': '445',
'DOI': '10.1016/j.pt.2014.07.005',
'article-title': 'Ivermectin: panacea for resource-poor communities ?',
'volume': '30',
'author': 'Crump',
'year': '2014',
'journal-title': 'Trends Parasitol.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib6',
'doi-asserted-by': 'crossref',
'first-page': '30',
'DOI': '10.9734/jammr/2020/v32i1030512',
'article-title': 'A\xa0wonder drug in the arsenal against COVID - 19: medication evidence '
'from ivermectin',
'volume': '32',
'author': 'Kumar',
'year': '2020',
'journal-title': 'J.\xa0Adv. Med. Med. Res.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib7',
'doi-asserted-by': 'crossref',
'first-page': '851',
'DOI': '10.1042/BJ20120150',
'article-title': 'Ivermectin is a specific inhibitor of importin α/β-mediated nuclear '
'import able to inhibit replication of HIV-1 and dengue virus',
'volume': '443',
'author': 'Wagstaff',
'year': '2012',
'journal-title': 'Biochem. J.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib8',
'doi-asserted-by': 'crossref',
'first-page': '301',
'DOI': '10.1016/j.antiviral.2013.06.002',
'article-title': 'Nuclear localization of dengue virus (DENV) 1-4 non-structural protein '
'5; protection against all 4 DENV serotypes by the inhibitor Ivermectin',
'volume': '99',
'author': 'Tay',
'year': '2013',
'journal-title': 'Antivir. Res.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib9',
'doi-asserted-by': 'crossref',
'first-page': '662',
'DOI': '10.1016/j.antiviral.2013.10.004',
'article-title': 'Nuclear import and export inhibitors alter capsid protein distribution '
'in mammalian cells and reduce Venezuelan Equine Encephalitis Virus '
'replication',
'volume': '100',
'author': 'Lundberg',
'year': '2013',
'journal-title': 'Antivir. Res.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib10',
'doi-asserted-by': 'crossref',
'first-page': '23138',
'DOI': '10.1038/srep23138',
'article-title': 'Influenza A viruses escape from MxA restriction at the expense of '
'efficient nuclear vRNP import',
'volume': '6',
'author': 'Gotz',
'year': '2016',
'journal-title': 'Sci. Rep.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib11',
'doi-asserted-by': 'crossref',
'first-page': '104760',
'DOI': '10.1016/j.antiviral.2020.104760',
'article-title': 'The broad spectrum antiviral ivermectin targets the host nuclear '
'transport importin α/β1 heterodimer',
'volume': '177',
'author': 'Yang',
'year': '2020',
'journal-title': 'Antivir. Res.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib12',
'doi-asserted-by': 'crossref',
'first-page': '1884',
'DOI': '10.1093/jac/dks147',
'article-title': 'Ivermectin is a potent inhibitor of flavivirus replication specifically '
'targeting NS3 helicase activity: new prospects for an old drug',
'volume': '67',
'author': 'Mastrangelo',
'year': '2012',
'journal-title': 'J.\xa0Antimicrob. Chemother.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib13',
'doi-asserted-by': 'crossref',
'first-page': '23',
'DOI': '10.1038/s41598-017-18742-8',
'article-title': 'Recognition by host nuclear transport proteins drives disorder-to-order '
'transition in Hendra virus V',
'volume': '8',
'author': 'Atkinson',
'year': '2018',
'journal-title': 'Sci. Rep.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib14',
'doi-asserted-by': 'crossref',
'first-page': '50',
'DOI': '10.1016/j.ceb.2019.01.001',
'article-title': 'Inhibitors of nuclear transport',
'volume': '58',
'author': 'Jans',
'year': '2019',
'journal-title': 'Curr. Opin. Cell Biol.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib15',
'doi-asserted-by': 'crossref',
'first-page': '117',
'DOI': '10.1016/j.antiviral.2015.12.012',
'article-title': 'Discovery of berberine, abamectin and ivermectin as antivirals against '
'chikungunya and other alphaviruses',
'volume': '126',
'author': 'Varghese',
'year': '2016',
'journal-title': 'Antivir. Res.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib16',
'doi-asserted-by': 'crossref',
'first-page': '8',
'DOI': '10.1016/j.antiviral.2018.01.007',
'article-title': 'Identification of novel antivirals inhibiting recognition of Venezuelan '
'equine encephalitis virus capsid protein by the Importin α/β1 '
'heterodimer through high-throughput screening',
'volume': '151',
'author': 'Thomas',
'year': '2018',
'journal-title': 'Antivir. Res.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib17',
'doi-asserted-by': 'crossref',
'first-page': '104787',
'DOI': '10.1016/j.antiviral.2020.104787',
'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 '
'in\xa0vitro',
'volume': '178',
'author': 'Caly',
'year': '2020',
'journal-title': 'Antivir. Res.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib18',
'doi-asserted-by': 'crossref',
'first-page': '55',
'DOI': '10.1016/j.antiviral.2018.09.010',
'article-title': 'Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance '
'into the nucleus and proliferation of the virus in\xa0vitro and vivo',
'volume': '159',
'author': 'Lv',
'year': '2018',
'journal-title': 'Antivir. Res.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib19',
'doi-asserted-by': 'crossref',
'first-page': '110',
'DOI': '10.1016/j.virol.2014.10.013',
'article-title': 'Role of a nuclear localization signal on the minor capsid proteins VP2 '
'and VP3 in BKPyV nuclear entry',
'volume': '474',
'author': 'Bennett',
'year': '2015',
'journal-title': 'Virology'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib20',
'doi-asserted-by': 'crossref',
'article-title': 'Inhibition of human adenovirus replication by the importin α/β1 nuclear '
'import inhibitor ivermectin',
'author': 'King',
'year': '2020',
'journal-title': 'J.\xa0Virol.',
'DOI': '10.1128/JVI.00710-20'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib21',
'doi-asserted-by': 'crossref',
'first-page': '33',
'DOI': '10.5802/crbiol.8',
'article-title': 'A\xa0nicotinic hypothesis for Covid-19 with preventive and therapeutic '
'implications',
'volume': '343',
'author': 'Changeux',
'year': '2020',
'journal-title': 'Comptes Rendus Biol.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib22',
'doi-asserted-by': 'crossref',
'first-page': '283',
'DOI': '10.1124/mol.53.2.283',
'article-title': 'A\xa0positive allosteric effector of the alpha7 neuronal nicotinic '
'acetylcholine receptor',
'volume': '53',
'author': 'Krause',
'year': '1998',
'journal-title': 'Mol. Pharmacol.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib23',
'series-title': 'Goodman & Gilman’s the Pharmacological Basis of Therapeutics',
'first-page': '1073',
'article-title': 'Chemotherapy of helminth infections',
'author': 'Loukas',
'year': '2006'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib24',
'doi-asserted-by': 'crossref',
'first-page': '827',
'DOI': '10.1093/jac/dkz524',
'article-title': 'Safety of high-dose ivermectin: a systematic review and meta-analysis',
'volume': '75',
'author': 'Navarro',
'year': '2020',
'journal-title': 'J.\xa0Antimicrob. Chemother.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib25',
'doi-asserted-by': 'crossref',
'first-page': '820',
'DOI': '10.1046/j.1365-3156.2003.01091.x',
'article-title': 'Variation in incidence of serious adverse events after onchocerciasis '
'treatment with ivermectin in areas of Cameroon co-endemic for loiasis',
'volume': '8',
'author': 'Twum-Danso',
'year': '2003',
'journal-title': 'Trop. Med. Int. Health'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib26',
'doi-asserted-by': 'crossref',
'first-page': '1122',
'DOI': '10.1177/009127002401382731',
'article-title': 'Safety, tolerability, and pharmacokinetics of escalating high doses of '
'ivermectin in healthy adult subjects',
'volume': '42',
'author': 'Guzzo',
'year': '2002',
'journal-title': 'J.\xa0Clin. Pharmacol.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib27',
'doi-asserted-by': 'crossref',
'first-page': '2176',
'DOI': '10.1016/j.bbamcr.2011.03.019',
'article-title': 'Regulation of nucleocytoplasmic trafficking of viral proteins; an '
'integral role in pathogenesis ?',
'volume': '1813',
'author': 'Fulcher',
'year': '2011',
'journal-title': 'Biochim. Biophys. Acta Mol. Cell Res.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib28',
'doi-asserted-by': 'crossref',
'first-page': '202',
'DOI': '10.1016/j.antiviral.2012.06.008',
'article-title': 'Nuclear trafficking of proteins from RNA viruses: potential target for '
'anti-virals?',
'volume': '95',
'author': 'Caly',
'year': '2012',
'journal-title': 'Antivir. Res.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib29',
'doi-asserted-by': 'crossref',
'first-page': '9812',
'DOI': '10.1128/JVI.01012-07',
'article-title': 'Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 '
'function by sequestering nuclear import factors on the rough '
'endoplasmic reticulum/golgi membrane',
'volume': '81',
'author': 'Frieman',
'year': '2007',
'journal-title': 'J.\xa0Virol.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib30',
'doi-asserted-by': 'crossref',
'first-page': '17554',
'DOI': '10.1038/srep17554',
'article-title': 'Middle East respiratory syndrome coronavirus ORF4b protein inhibits '
'type I interferon production through both cytoplasmic and nuclear '
'targets',
'volume': '5',
'author': 'Yang',
'year': '2015',
'journal-title': 'Sci. Rep.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib31',
'doi-asserted-by': 'crossref',
'first-page': '281',
'DOI': '10.3390/cells8030281',
'article-title': 'Novel flavivirus antiviral that targets the host nuclear transport '
'importin α/β1 heterodimer',
'volume': '8',
'author': 'Yang',
'year': '2019',
'journal-title': 'Cells'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib32',
'doi-asserted-by': 'crossref',
'first-page': '795',
'DOI': '10.1111/j.1600-0854.2007.00579.x',
'article-title': 'Nuclear localization of dengue virus nonstructural protein 5 through '
'its importin alpha/beta-recognized nuclear localization sequences is '
'integral to viral infection',
'volume': '8',
'author': 'Pryor',
'year': '2007',
'journal-title': 'Traffic'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib33',
'doi-asserted-by': 'crossref',
'first-page': '1780',
'DOI': '10.1093/infdis/jiu319',
'article-title': 'A\xa0nuclear transport inhibitor that modulates the unfolded protein '
'response and provides in\xa0vivo protection against lethal dengue virus '
'infection',
'volume': '210',
'author': 'Fraser',
'year': '2014',
'journal-title': 'J.\xa0Infect. Dis.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib34',
'doi-asserted-by': 'crossref',
'first-page': '192',
'DOI': '10.1177/1087057110390360',
'article-title': 'An AlphaScreen(R)-based assay for high-throughput screening for '
'specific inhibitors of nuclear import',
'volume': '16',
'author': 'Wagstaff',
'year': '2011',
'journal-title': 'J.\xa0Biomol. Screen'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib35',
'article-title': 'Molecular dissection of an inhibitor targeting the HIV integrase '
'dependent preintegration complex nuclear import',
'volume': '20',
'author': 'Wagstaff',
'year': '2018',
'journal-title': 'Cell Microbiol.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib36',
'doi-asserted-by': 'crossref',
'DOI': '10.1111/cmi.12848',
'article-title': 'Nucleocytoplasmic shuttling of the West Nile virus RNA-dependent RNA '
'polymerase NS5 is critical to infection',
'volume': '20',
'author': 'Lopez-Denman',
'year': '2018',
'journal-title': 'Cell Microbiol.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib37',
'doi-asserted-by': 'crossref',
'first-page': '449',
'DOI': '10.1111/j.1472-8206.2009.00684.x',
'article-title': 'Avermectin exerts anti-inflammatory effect by downregulating the '
'nuclear transcription factor kappa-B and mitogen-activated protein '
'kinase activation pathway',
'author': 'Ci',
'year': '2009',
'journal-title': 'Fund. Clin. Pharmacol.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib38',
'doi-asserted-by': 'crossref',
'first-page': '524',
'DOI': '10.1007/s00011-008-8007-8',
'article-title': 'Ivermectin inhibits LPS-induced production of inflammatory cytokines '
'and improves LPS-induced survival in mice',
'volume': '57',
'author': 'Zhang',
'year': '2008',
'journal-title': 'Inflamm. Res.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib39',
'doi-asserted-by': 'crossref',
'article-title': 'Prioritisation of anti-SARS-cov-2 drug repurposing opportunities based '
'on plasma and target site concentrations derived from their established '
'human pharmacokinetics',
'author': 'Arshad',
'year': '2020',
'journal-title': 'Clin. Pharmacol. Ther.',
'DOI': '10.1002/cpt.1909'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib40',
'doi-asserted-by': 'crossref',
'article-title': 'The approved dose of ivermectin alone is not the ideal dose for the '
'treatment of COVID-19',
'author': 'Schmith',
'year': '2020',
'journal-title': 'Clin. Pharmacol. Ther.',
'DOI': '10.1002/cpt.1889'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib41',
'series-title': '34th Annual Meeting the Royal College of Physicians of Thailand- '
'‘Internal Medicine and One Health’',
'article-title': 'Efficacy and safety of ivermectin against dengue infection: a phase '
'III, randomized, double-blind, placebo-controlled trial',
'author': 'Yamasmith',
'year': '2018'},
{'key': '10.1016/j.bbrc.2020.10.042_bib42', 'author': 'US Food and Drug Administration'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib43',
'series-title': 'FDA Cautions against Use of Hydroxychloroquine or Chloroquine for '
'COVID-19 outside of the Hospital Setting or a Clinical Trial Due to Risk '
'of Heart Rhythm Problems',
'author': 'US Food and Drug Administration',
'year': '2020'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib45',
'series-title': 'Ministerial Resolution No 259 from the Gobierno del Estate Plurinacional '
'de Bolivia Misterio de Salud',
'year': '2020'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib46',
'first-page': '129',
'article-title': 'Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on '
'COVID-19 infected patients: a proof of concept study',
'volume': '31',
'author': 'Espitia-Hernandez',
'year': '2020',
'journal-title': 'Biomed. Res.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib47',
'series-title': 'Eurnekian Public Hospital Argentina’s IVERCAR Ivermectin & Carrageenan '
'Study Shows Positive Results Targeting COVID-19. September 3',
'author': 'Trial Site News',
'year': '2020'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib48',
'article-title': 'Outcome of ivermectin treated mild to moderate COVID-19 cases: a '
'single-centre, open-label, randomised controlled study',
'volume': '14',
'author': 'Podder',
'year': '2020',
'journal-title': 'IMC J. Med. Sci.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib49',
'series-title': 'Ivermectin Treatment May Improve the Prognosis of Patients with COVID-19',
'author': 'Khan',
'year': '2020'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib50',
'article-title': 'Use of ivermectin is associated with lower mortality in hospitalized '
'patients with COVID-19 (ICON study)',
'author': 'Rajter',
'year': '2020',
'journal-title': 'Chest'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib51',
'doi-asserted-by': 'crossref',
'first-page': '10',
'DOI': '10.3329/jbcps.v38i0.47512',
'article-title': 'A\xa0case series of 100 COVID-19 positive patients treated with '
'combination of ivermectin and doxycycline',
'volume': '38',
'author': 'Alam',
'year': '2020',
'journal-title': 'Bangladesh Coll. Phys. Surg.'},
{ 'key': '10.1016/j.bbrc.2020.10.042_bib52',
'doi-asserted-by': 'crossref',
'first-page': '5',
'DOI': '10.3329/jbcps.v38i0.47514',
'article-title': 'Comparison of viral clearance between ivermectin with doxycycline and '
'hydroxychloroquine with azithromycin in COVID-19 patients',
'volume': '38',
'author': 'Rahman',
'year': '2020',
'journal-title': 'Bangladesh Coll. Phys. Surg.'}],
'container-title': 'Biochemical and Biophysical Research Communications',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0006291X20319598?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S0006291X20319598?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2021, 3, 23]],
'date-time': '2021-03-23T15:39:37Z',
'timestamp': 1616513977000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0006291X20319598'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 1]]},
'references-count': 49,
'alternative-id': ['S0006291X20319598'],
'URL': 'http://dx.doi.org/10.1016/j.bbrc.2020.10.042',
'relation': {},
'ISSN': ['0006-291X'],
'subject': ['Cell Biology', 'Molecular Biology', 'Biochemistry', 'Biophysics'],
'container-title-short': 'Biochemical and Biophysical Research Communications',
'published': {'date-parts': [[2021, 1]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'The broad spectrum host-directed agent ivermectin as an antiviral for '
'SARS-CoV-2 ?',
'name': 'articletitle',
'label': 'Article Title'},
{ 'value': 'Biochemical and Biophysical Research Communications',
'name': 'journaltitle',
'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.bbrc.2020.10.042',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{'value': '© 2020 Published by Elsevier Inc.', 'name': 'copyright', 'label': 'Copyright'}]}
